Xspray Pharma AB publishes its Annual Report for 2024

Regulatory press release 2025-03-27

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today publishes its Annual Report for the financial year 2024.

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:

“In 2024, we finalized the foundation for Xspray Pharma’s transformation from an innovative, research-driven company into a commercial drug company. We have addressed regulatory challenges, conducted market preparations and secured funding to launch our first product, Dasynoc®, in the US market in 2025.”

The annual report is attached, and can also be downloaded from the company's website, www.xspraypharma.com.

For further information, please contact:

Per Andersson, CEO
Xspray Pharma AB (publ)
Tel: + 46 (0)8 730 37 00
E-mail: per.andersson@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-27 08:00 CET.

Attachments

20250327 Xspray Annual Report 2024 Eng
549300NGRQCNZ3X4L157-2024-12-31-sv (Final)